Acute effects of GIP and GLP ‐1 receptor antagonism in totally pancreatectomized individuals: A randomized double‐blind, placebo‐controlled crossover study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70186 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Liva S L Krogh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Hauptthemen laut MEDLINE: Gastric Inhibitory Polypeptide, Receptors, Gastrointestinal Hormone, Peptide Fragments, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: European Foundation for the Study of Diabetes, A P Moller Foundation.
Abstract (Originalsprache)
Aims
The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide 1 (GLP‐1) influence metabolism through strong effects on pancreatic hormone secretion but also in a pancreas‐independent manner. Here, we investigated the isolated extrapancreatic effects of endogenous GIP and GLP‐1 by applying hormone receptor antagonists in totally pancreatectomized individuals.
Methods
Twelve totally pancreatectomized individuals each underwent four 270‐min liquid mixed meal tests (480 kcal) in a randomized study design with infusions of the GIP receptor antagonist GIP(3‐30)NH 2 (800 pmol/kg/min), the GLP‐1 receptor antagonist exendin(9‐39)NH 2 (450 pmol/kg/min), GIP(3‐30)NH 2 + exendin(9‐39)NH 2 , and saline (placebo), respectively. Blood samples, appetite‐related measures, heart rate, blood pressure, and ad libitum food intake data were collected. Participants continued their basal insulin but omitted bolus insulin in the morning of the experiment.
Results
Infusions of GIP(3‐30)NH 2 and GIP(3‐30)NH 2 + exendin(9‐39)NH 2 attenuated meal‐induced inhibition of bone resorption (carboxy‐terminal collagen crosslinks) (nadir [mean ± SD] to 84 ± 9% and to 85 ± 8% of baseline, compared to placebo (64 ± 15%) ( p s
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
- Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
- Novo Nordisk A/S, Bagsværd, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Jens J Holst, Lærke S Gasbjerg
Förderung
- European Foundation for the Study of Diabetes
- A P Moller Foundation
Zitieren
APA
Krogh, L. S. L., Helsted, M. M., Englund, A., Bergmann, N. C., Skov-Jeppesen, K., Nielsen, C. K., Hansen, C. P., Rosenkilde, M. M., Hartmann, B., Holst, J. J., Knop, F. K., Lund, A. B., & Gasbjerg, L. S. (2026). Acute effects of GIP and GLP ‐1 receptor antagonism in totally pancreatectomized individuals: A randomized double‐blind, placebo‐controlled crossover study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70186
Vancouver
Krogh LSL, Helsted MM, Englund A, Bergmann NC, Skov-Jeppesen K, Nielsen CK, et al. Acute effects of GIP and GLP ‐1 receptor antagonism in totally pancreatectomized individuals: A randomized double‐blind, placebo‐controlled crossover study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70186
BibTeX
@article{Krogh2026,
author = {Krogh, Liva S L and Helsted, Mads M and Englund, Anders and Bergmann, Natasha C and Skov-Jeppesen, Kirsa and Nielsen, Casper K and Hansen, Carsten P and Rosenkilde, Mette M and Hartmann, Bolette and Holst, Jens J and Knop, Filip K and Lund, Asger B and Gasbjerg, Lærke S},
title = {Acute effects of GIP and GLP ‐1 receptor antagonism in totally pancreatectomized individuals: A randomized double‐blind, placebo‐controlled crossover study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70186}
}
EUVIMED